Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Bexagliflozin in Healthy Males
NCT03417076Phase 1Withdrawn
- Sponsor
- Theracos, Inc.
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bexagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Theracos, Inc. Primary endpoint: Absolute Bioavailability (Fp.o.) up to 48 hours. Planned start Aug 2018; status: withdrawn.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03417076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417076.